INDV Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. (INDV) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.4M.
Where they traded
Last open-market purchase: August 27, 2026 , by Anderson Woodrow D .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Anderson Woodrow D | Chief Accounting Officer | Buy | 1,500 | $35.69 | $53.5K | 27,638 | |
| Anderson Woodrow D | Chief Accounting Officer | Buy | 1,500 | $36.28 | $54.4K | 26,138 | |
| Heidbreder Christian | Chief Scientific Officer | Sell 10b5-1 | 18,586 | $41.14 | $764.6K | 209,337 −8.2% of holding | |
| Heidbreder Christian | Chief Scientific Officer | Sell 10b5-1 | 18,586 | $38.06 | $707.4K | 227,923 −7.5% of holding | |
| Preblick Ryan | Chief Financial Officer | Sell 10b5-1 | 36,000 | $37.70 | $1.4M | 284,751 −11.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.